1. Home
  2. STRA vs NUVB Comparison

STRA vs NUVB Comparison

Compare STRA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STRA

Strategic Education Inc.

HOLD

Current Price

$80.68

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.52

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRA
NUVB
Founded
2017
2018
Country
United States
United States
Employees
N/A
291
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
STRA
NUVB
Price
$80.68
$4.52
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$92.67
$11.38
AVG Volume (30 Days)
253.1K
3.2M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
2.91%
N/A
EPS Growth
15.85
N/A
EPS
5.41
N/A
Revenue
$997,137,000.00
N/A
Revenue This Year
$3.93
$205.55
Revenue Next Year
$4.93
$58.57
P/E Ratio
$15.25
N/A
Revenue Growth
57.23
N/A
52 Week Low
$72.17
$1.57
52 Week High
$92.98
$9.75

Technical Indicators

Market Signals
Indicator
STRA
NUVB
Relative Strength Index (RSI) 45.06 46.60
Support Level $78.87 $4.06
Resistance Level $81.59 $5.55
Average True Range (ATR) 2.37 0.24
MACD -0.16 0.08
Stochastic Oscillator 23.00 59.35

Price Performance

Historical Comparison
STRA
NUVB

About STRA Strategic Education Inc.

Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: